Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer

Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-neg...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radioanalytical and nuclear chemistry 2019-11, Vol.322 (2), p.237-248
Main Authors: Vahidfar, Nasim, Fallahpoor, Maryam, Farzanehfar, Saeed, Divband, Ghasemali, Ahmadzadehfar, Hojjat
Format: Article
Language:English
Subjects:
Amino acids
Antigens
Chemistry
Chemistry and Materials Science
Diagnostic Radiology
Dosimeters
Hadrons
Heavy Ions
Inorganic Chemistry
Monoclonal antibodies
Nuclear Chemistry
Nuclear Physics
Pharmacology
Physical Chemistry
Physical properties
Prostate cancer
Radiochemistry
Tracers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c386t-81cfb944c25f8470ca98bfbcf9d56f54b3d3910847abedb1ec0a017ae35a813
cites cdi_FETCH-LOGICAL-c386t-81cfb944c25f8470ca98bfbcf9d56f54b3d3910847abedb1ec0a017ae35a813
container_end_page 248
container_issue 2
container_start_page 237
container_title Journal of radioanalytical and nuclear chemistry
container_volume 322
creator Vahidfar, Nasim
Fallahpoor, Maryam
Farzanehfar, Saeed
Divband, Ghasemali
Ahmadzadehfar, Hojjat
description Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-negative. When radiolabeled, PSMA tracers show outstanding features in terms of their theranostic properties. In this study, we discuss the pharmacological and physical characteristics of various radiopharmaceuticals used for the theranostic treatment of PCa. This review aims to outline the developments from the first radiopharmaceuticals PCa, including monoclonal antibodies, to the final gold standard in PSMA-based theranostics.
doi_str_mv 10.1007/s10967-019-06800-6
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2311374037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A604652411</galeid><sourcerecordid>A604652411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-81cfb944c25f8470ca98bfbcf9d56f54b3d3910847abedb1ec0a017ae35a813</originalsourceid><addsrcrecordid>eNp9kUFr3DAQhUVpoJukf6AnQc9KR5Yty8cltE0hpYX0LsbyaKNgW1tJScm_jzZbCIVQdBCaed-bEY-xDxIuJED_KUsYdC9ADgK0ARD6DdvIzhjR9Abesg00SouuV_IdO835DgAGY9SGLVchl5iCw5knegj0h0fP97eYFnRxjrvnzkQPNMf9QmvhuE58ijksVNLjQfzz5vtWjJhp4uWWEq4xl-Ay9zHxfaoPLMQdro7SOTvxOGd6__c-YzdfPv-6vBLXP75-u9xeC6eMLsJI58ehbV3TedP24HAwox-dH6ZO-64d1aQGCbWFI02jJAcIskdSHRqpztjHo2ud_vuecrF38T6tdaBtlJSqb0H1L6odzmTD6mNJ6JaQnd1qaHXXtPLgdfGKqp6JluDiSj7U-j9AcwRc_XpO5O0-hQXTo5VgD1nZY1a2ZmWfs7K6QuoI5Sped5ReNv4P9QQBoZez</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2311374037</pqid></control><display><type>article</type><title>Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer</title><source>Springer Nature</source><creator>Vahidfar, Nasim ; Fallahpoor, Maryam ; Farzanehfar, Saeed ; Divband, Ghasemali ; Ahmadzadehfar, Hojjat</creator><creatorcontrib>Vahidfar, Nasim ; Fallahpoor, Maryam ; Farzanehfar, Saeed ; Divband, Ghasemali ; Ahmadzadehfar, Hojjat</creatorcontrib><description>Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-negative. When radiolabeled, PSMA tracers show outstanding features in terms of their theranostic properties. In this study, we discuss the pharmacological and physical characteristics of various radiopharmaceuticals used for the theranostic treatment of PCa. This review aims to outline the developments from the first radiopharmaceuticals PCa, including monoclonal antibodies, to the final gold standard in PSMA-based theranostics.</description><identifier>ISSN: 0236-5731</identifier><identifier>EISSN: 1588-2780</identifier><identifier>DOI: 10.1007/s10967-019-06800-6</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Amino acids ; Antigens ; Chemistry ; Chemistry and Materials Science ; Diagnostic Radiology ; Dosimeters ; Hadrons ; Heavy Ions ; Inorganic Chemistry ; Monoclonal antibodies ; Nuclear Chemistry ; Nuclear Physics ; Pharmacology ; Physical Chemistry ; Physical properties ; Prostate cancer ; Radiochemistry ; Tracers</subject><ispartof>Journal of radioanalytical and nuclear chemistry, 2019-11, Vol.322 (2), p.237-248</ispartof><rights>Akadémiai Kiadó, Budapest, Hungary 2019</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Copyright Springer Nature B.V. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-81cfb944c25f8470ca98bfbcf9d56f54b3d3910847abedb1ec0a017ae35a813</citedby><cites>FETCH-LOGICAL-c386t-81cfb944c25f8470ca98bfbcf9d56f54b3d3910847abedb1ec0a017ae35a813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Vahidfar, Nasim</creatorcontrib><creatorcontrib>Fallahpoor, Maryam</creatorcontrib><creatorcontrib>Farzanehfar, Saeed</creatorcontrib><creatorcontrib>Divband, Ghasemali</creatorcontrib><creatorcontrib>Ahmadzadehfar, Hojjat</creatorcontrib><title>Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer</title><title>Journal of radioanalytical and nuclear chemistry</title><addtitle>J Radioanal Nucl Chem</addtitle><description>Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-negative. When radiolabeled, PSMA tracers show outstanding features in terms of their theranostic properties. In this study, we discuss the pharmacological and physical characteristics of various radiopharmaceuticals used for the theranostic treatment of PCa. This review aims to outline the developments from the first radiopharmaceuticals PCa, including monoclonal antibodies, to the final gold standard in PSMA-based theranostics.</description><subject>Amino acids</subject><subject>Antigens</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Diagnostic Radiology</subject><subject>Dosimeters</subject><subject>Hadrons</subject><subject>Heavy Ions</subject><subject>Inorganic Chemistry</subject><subject>Monoclonal antibodies</subject><subject>Nuclear Chemistry</subject><subject>Nuclear Physics</subject><subject>Pharmacology</subject><subject>Physical Chemistry</subject><subject>Physical properties</subject><subject>Prostate cancer</subject><subject>Radiochemistry</subject><subject>Tracers</subject><issn>0236-5731</issn><issn>1588-2780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kUFr3DAQhUVpoJukf6AnQc9KR5Yty8cltE0hpYX0LsbyaKNgW1tJScm_jzZbCIVQdBCaed-bEY-xDxIuJED_KUsYdC9ADgK0ARD6DdvIzhjR9Abesg00SouuV_IdO835DgAGY9SGLVchl5iCw5knegj0h0fP97eYFnRxjrvnzkQPNMf9QmvhuE58ijksVNLjQfzz5vtWjJhp4uWWEq4xl-Ay9zHxfaoPLMQdro7SOTvxOGd6__c-YzdfPv-6vBLXP75-u9xeC6eMLsJI58ehbV3TedP24HAwox-dH6ZO-64d1aQGCbWFI02jJAcIskdSHRqpztjHo2ud_vuecrF38T6tdaBtlJSqb0H1L6odzmTD6mNJ6JaQnd1qaHXXtPLgdfGKqp6JluDiSj7U-j9AcwRc_XpO5O0-hQXTo5VgD1nZY1a2ZmWfs7K6QuoI5Sped5ReNv4P9QQBoZez</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Vahidfar, Nasim</creator><creator>Fallahpoor, Maryam</creator><creator>Farzanehfar, Saeed</creator><creator>Divband, Ghasemali</creator><creator>Ahmadzadehfar, Hojjat</creator><general>Springer International Publishing</general><general>Springer</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191101</creationdate><title>Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer</title><author>Vahidfar, Nasim ; Fallahpoor, Maryam ; Farzanehfar, Saeed ; Divband, Ghasemali ; Ahmadzadehfar, Hojjat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-81cfb944c25f8470ca98bfbcf9d56f54b3d3910847abedb1ec0a017ae35a813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Amino acids</topic><topic>Antigens</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Diagnostic Radiology</topic><topic>Dosimeters</topic><topic>Hadrons</topic><topic>Heavy Ions</topic><topic>Inorganic Chemistry</topic><topic>Monoclonal antibodies</topic><topic>Nuclear Chemistry</topic><topic>Nuclear Physics</topic><topic>Pharmacology</topic><topic>Physical Chemistry</topic><topic>Physical properties</topic><topic>Prostate cancer</topic><topic>Radiochemistry</topic><topic>Tracers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vahidfar, Nasim</creatorcontrib><creatorcontrib>Fallahpoor, Maryam</creatorcontrib><creatorcontrib>Farzanehfar, Saeed</creatorcontrib><creatorcontrib>Divband, Ghasemali</creatorcontrib><creatorcontrib>Ahmadzadehfar, Hojjat</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of radioanalytical and nuclear chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vahidfar, Nasim</au><au>Fallahpoor, Maryam</au><au>Farzanehfar, Saeed</au><au>Divband, Ghasemali</au><au>Ahmadzadehfar, Hojjat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer</atitle><jtitle>Journal of radioanalytical and nuclear chemistry</jtitle><stitle>J Radioanal Nucl Chem</stitle><date>2019-11-01</date><risdate>2019</risdate><volume>322</volume><issue>2</issue><spage>237</spage><epage>248</epage><pages>237-248</pages><issn>0236-5731</issn><eissn>1588-2780</eissn><abstract>Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-negative. When radiolabeled, PSMA tracers show outstanding features in terms of their theranostic properties. In this study, we discuss the pharmacological and physical characteristics of various radiopharmaceuticals used for the theranostic treatment of PCa. This review aims to outline the developments from the first radiopharmaceuticals PCa, including monoclonal antibodies, to the final gold standard in PSMA-based theranostics.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s10967-019-06800-6</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0236-5731
ispartof Journal of radioanalytical and nuclear chemistry, 2019-11, Vol.322 (2), p.237-248
issn 0236-5731
1588-2780
language eng
recordid cdi_proquest_journals_2311374037
source Springer Nature
subjects Amino acids
Antigens
Chemistry
Chemistry and Materials Science
Diagnostic Radiology
Dosimeters
Hadrons
Heavy Ions
Inorganic Chemistry
Monoclonal antibodies
Nuclear Chemistry
Nuclear Physics
Pharmacology
Physical Chemistry
Physical properties
Prostate cancer
Radiochemistry
Tracers
title Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T06%3A52%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Historical%20review%20of%20pharmacological%20development%20and%20dosimetry%20of%20PSMA-based%20theranostics%20for%20prostate%20cancer&rft.jtitle=Journal%20of%20radioanalytical%20and%20nuclear%20chemistry&rft.au=Vahidfar,%20Nasim&rft.date=2019-11-01&rft.volume=322&rft.issue=2&rft.spage=237&rft.epage=248&rft.pages=237-248&rft.issn=0236-5731&rft.eissn=1588-2780&rft_id=info:doi/10.1007/s10967-019-06800-6&rft_dat=%3Cgale_proqu%3EA604652411%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c386t-81cfb944c25f8470ca98bfbcf9d56f54b3d3910847abedb1ec0a017ae35a813%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2311374037&rft_id=info:pmid/&rft_galeid=A604652411&rfr_iscdi=true